Drugs / THDBH120
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06951945 | Jul → Dec 2024 | obesity disorder | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT07020949 | Jun → Nov 2024 | type 2 diabetes mellitus | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06744868 | Dec 2023 → Sep 2024 | — | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07036601 | Jan 2025 → Feb 2026 overdue | obesity disorder | Tonghua Dongbao Pharmaceutical Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THDBH120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06744868 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT06744868 ↗ |